Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients

 Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients

Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria Type 1 (PH1) in Pediatric Patients

Shots:

  • The P-III ILLUMINATE-B study will assess Lumasiran in 8 patients with primary hyperoxaluria type 1 (PH1) aged < 6yrs., associated 1EPs as reduction of urinary oxalate in 6mos. & 2EPs as evaluating glomerular filtration rate (GFR), safety, tolerability, with its expected initial results in mid-2020
  • The company also reports the result of P-II OLE study result assessing lumasiran (1.0 & 3.0 mg/kg monthly, and 3.0 mg/kg quarterly) in patients and resulted in 72% reduction in urinary oxalate excretion, mean reduction relative to baseline 69%; 77% reduction in urinary 24-hour oxalate : creatinine ratio
  • Lumasiran (formerly ALN-GO1, SC) is an RNAi therapeutics targeting glycolate oxidase (GO) and has received FDA’s BT & ODD, EU’s ODD & EMA’s PRIME Designation

Click here to read full press release/ article | Ref: Alnylam | Image: FDA Headlines

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post